Historical Valuation
Elicio Therapeutics Inc (ELTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.80. The fair price of Elicio Therapeutics Inc (ELTX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：8.06
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Elicio Therapeutics Inc (ELTX) has a current Price-to-Book (P/B) ratio of 36.41. Compared to its 3-year average P/B ratio of 11.18 , the current P/B ratio is approximately 225.69% higher. Relative to its 5-year average P/B ratio of 11.18, the current P/B ratio is about 225.69% higher. Elicio Therapeutics Inc (ELTX) has a Forward Free Cash Flow (FCF) yield of approximately -27.68%. Compared to its 3-year average FCF yield of -42.10%, the current FCF yield is approximately -34.24% lower. Relative to its 5-year average FCF yield of -42.10% , the current FCF yield is about -34.24% lower.
P/B
Median3y
11.18
Median5y
11.18
FCF Yield
Median3y
-42.10
Median5y
-42.10
Competitors Valuation Multiple
AI Analysis for ELTX
The average P/S ratio for ELTX competitors is 11.44, providing a benchmark for relative valuation. Elicio Therapeutics Inc Corp (ELTX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ELTX
1Y
3Y
5Y
Market capitalization of ELTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ELTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ELTX currently overvalued or undervalued?
Elicio Therapeutics Inc (ELTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.80. The fair price of Elicio Therapeutics Inc (ELTX) is between to according to relative valuation methord.
What is Elicio Therapeutics Inc (ELTX) fair value?
ELTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Elicio Therapeutics Inc (ELTX) is between to according to relative valuation methord.
How does ELTX's valuation metrics compare to the industry average?
The average P/S ratio for ELTX's competitors is 11.44, providing a benchmark for relative valuation. Elicio Therapeutics Inc Corp (ELTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Elicio Therapeutics Inc (ELTX) as of Jan 10 2026?
As of Jan 10 2026, Elicio Therapeutics Inc (ELTX) has a P/B ratio of 36.41. This indicates that the market values ELTX at 36.41 times its book value.
What is the current FCF Yield for Elicio Therapeutics Inc (ELTX) as of Jan 10 2026?
As of Jan 10 2026, Elicio Therapeutics Inc (ELTX) has a FCF Yield of -27.68%. This means that for every dollar of Elicio Therapeutics Inc’s market capitalization, the company generates -27.68 cents in free cash flow.
What is the current Forward P/E ratio for Elicio Therapeutics Inc (ELTX) as of Jan 10 2026?
As of Jan 10 2026, Elicio Therapeutics Inc (ELTX) has a Forward P/E ratio of -5.06. This means the market is willing to pay $-5.06 for every dollar of Elicio Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Elicio Therapeutics Inc (ELTX) as of Jan 10 2026?
As of Jan 10 2026, Elicio Therapeutics Inc (ELTX) has a Forward P/S ratio of 0.00. This means the market is valuing ELTX at $0.00 for every dollar of expected revenue over the next 12 months.